Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 6/20 | 0.51 |
| ▸ | HTR7 | P34969 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750487 | 1.00 | HRH2 (0.51) | HRH2HTR7ALDH1A1KMT2APTK2B | |
| SCHEMBL21750489 | 1.00 | HRH2 (0.51) | HRH2HTR7ALDH1A1KMT2APTK2B | |
| SCHEMBL21769222 | 0.89 | MEN1 (0.60) | HTR7ALDH1A1KMT2ADRD2DRD1 | |
| SCHEMBL21769224 | 0.89 | MEN1 (0.60) | HTR7ALDH1A1KMT2ADRD2DRD1 | |
| SCHEMBL21750486 | 0.82 | KDM4E (0.70) | HRH2ALDH1A1KMT2ADRD2DRD1 | |
| SCHEMBL21750482 | 0.81 | KMT2A (0.66) | HTR7ALDH1A1KMT2ADRD2DRD1 | |
| SCHEMBL21769226 | 0.80 | DRD3 (0.44) | HTR7ALDH1A1DRD2DRD3HTR1A | |
| SCHEMBL21769227 | 0.80 | DRD3 (0.44) | HTR7ALDH1A1DRD2DRD3HTR1A | |
| SCHEMBL21750484 | 0.77 | ALDH1A1 (0.70) | ALDH1A1KMT2APTK2BDRD2DRD1 | |
| SCHEMBL11365759 | 0.76 | DRD2 (0.75) | ALDH1A1KMT2APTK2BDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | HRH2 1784/4885HTR7 222/4885ALDH1A1 1721/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | HRH2 1784/4885HTR7 222/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.